Pharmaceutical Pricing, Reimbursement & Market Access
Lanton Strategies International advises pharmaceutical and biotechnology companies on how U.S. and European drug pricing, reimbursement and market access policies affect commercialization, launch planning and long-term revenue strategy.
U.S. drug pricing and reimbursement
We assess Medicare Part B and Part D, Medicaid drug rebate policy, the 340B Drug Pricing Program, pharmacy benefit manager (PBM) regulation and commercial payer developments. We help manufacturers understand how these policies may affect coverage, distribution, contracting and patient access.
Market access and launch strategy
We support European and U.S. life sciences companies in evaluating reimbursement pathways, policy exposure and distribution considerations before entering new markets. Our advisory work connects government policy and regulatory developments with commercial planning.
International pricing and trade
We examine how most-favored-nation pricing proposals, international reference pricing, trade measures and changes to national reimbursement systems may affect cross-border launch sequencing and commercial strategy.
Our advisory services
Drug pricing and reimbursement policy analysis
Medicare, Medicaid, 340B and PBM policy assessment
Market access and commercialization risk assessment
International drug pricing and trade policy analysis
Executive briefings and government affairs strategy
For pharmaceutical pricing and market access advisory inquiries, contact LSI.